EphA2 是一种酪氨酸激酶受体，被认为是癌症中有希望的靶点。人们使用不同的方法来靶向EphA2受体，大量的临床前数据证明了该受体在临床肿瘤学中用于诊断和癌症治疗（包括免疫治疗）的潜在利用。在这篇综述中，我们总结了涉及EphA2靶向癌症的最新专利。为此，我们使用了涵盖 2018 年至今的专利数据库 Patentscope。在同行评审期刊上发表时，考虑了发明的临床前和临床数据。此外，如果有的话，clinicalTrial.gov 标识符（NCT 编号）也被包括在内。为了更容易、更直接地阅读，我们考虑到在临床肿瘤学中利用 EphA2 的发明的性质（适体、小分子、抗体、肽、抗原和嵌合抗原受体），将专利分为不同类别。尽管化学成分多种多样，但目前还没有批准的针对 EphA2 的抗癌药物。然而，这些知识产权，其中一些得到了强有力的临床前证据的支持，让我们在发现 30 多年后，最终将看到第一个 EphA2 靶向药物在临床肿瘤学中获得批准。

EphA2 is a tyrosine kinase receptor and is considered a promising target in cancer. Different approaches are used to target EphA2 receptor, and a lot of preclinical data demonstrate the potential exploitation of this receptor in clinical oncology for diagnosis and cancer therapy, including immunotherapy.In this review, we have summarized the recent patents involving the EphA2 targeting in cancer. For this aim, we used the patent database Patentscope covering the time period of 2018-present. Preclinical and clinical data of the inventions were considered when published on peer reviewed journals. Moreover, the clinicalTrial.gov identifiers (NCT numbers) were included when available. For an easier and more immediate reading, we classify the patents in different categories, considering the nature (aptamers, small molecules, antibodies, peptides, antigens and chimeric antigen receptors) of the inventions exploiting EphA2 in clinical oncology.Despite the availability of a plethora of chemically diverse agents, there are no approved anticancer drugs targeting EphA2 yet. However, these intellectual properties, some of which supported by strong preclinical evidence, keep the hope that, after more than 30 years from its discovery, we will finally see the first EphA2 targeting agent approved in clinical oncology.